bestdamnpennys4...'s  Instablog

Nuvilex, Inc. (NVLX), was formerly eFoodSafety.com, Inc until March of 2009. This company is independently operated along with it wholly owned subsidiaries and makes products to improve your health. Numilex makes Cinnergen, Cennechol, Infinitink, and Talysn Scar Cream.

This company was also researching and developing the product Oraphyte which is used on crops and turf grass, and is biodegradable nematocide as well as the product Citroxin which is a surface cleaner and is patented.

Cinnechol is a supplement to help with cholesterol and to help maintain it. This product is all natural and gluten free. The product Cinnergen is a liquid supplement that helps the body to produce glucose and may also help the body to reduce glucose absorption in the intestine and may also prevent diabetes type 1 and 2.

Infinitink is the only product like this on the market and is a permanent tattoo ink like any other, but can be more easily removed if needed through fewer laser treatments. The average to remove the ink was 2 treatments.

Oraphyte damages the skin of a nematode which in turn disrupts its immune system and naturally the environment kills it.

Talysn Scar Cream is a product that help promote healing in the body and help with the appearance of scars. In about 2-4 weeks you should be able to see results in your scar.

NVLX is currently trading for $.15. Over the past 52 weeks, this stock has seen a low trade of $.019 and a high of up to $.22. The high trade for the day is at $.18, so it just needs a little push to top that 52 week high. The previous close was $.1775. The market cap for this company is $66.84M.

For the most current and up to date information on NVLX and many other companies, subscribe to our FREE newsletter at bestdamnpennys4bucks.com

NVLX

Robert Ryan

Gerald W. Crabtree

Amanda Johnson

www.nuvilex.com/

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

International Commercial Television Inc (ICTL), based in Wayne, PA, is a company that sells health and beauty aid products. And everyone loves to look beautiful and feel healthy. Along with health and beauty the company also sells diet and fitness and toys through Informercial throughout the US. They utilize both long and short form advertising spots, reaping in sells through their direct audience internet users as well as television shopping networks and retail distributors. One of their best selling products includes DermaWand, which is a skin care appliance that instantly minimizes facial wrinkles and fine lines, amazingly improving skin condition. Besides DermaWand, ICTL also offers DermaVital, a re hydrating product that actually penetrates the skin. With a 432% increase in revenue for its 2nd quarter ending in June 2012 over it last year 2nd quarter earnings of 1,219,380 compared to this years 6,491,809 is something to celebrate. This is a totally transparent company investors should take a closer look at.

• International Commercial Television Inc was founded in 1998, and is Publicly held.
• International Commercial Television Inc had $3.1 Million in 2011 revenue (Actual data).
• International Commercial Television Inc employs 0-10people (Actual data).
• Of the 0-10 total International Commercial Television Inc employees, 0-10 (Estimated data) are located at the Single Location.
• International Commercial Television Inc trades on the OTC Bulletin Board Pink Sheets (PK) under the ICTL ticker symbol.

For the most current and up to date information on ICTL and many other companies, subscribe to our FREE newsletter at bestdamnpennys4bucks.com

ICTL

Kelvin Claney

Richard Ransom

ictvonline.com

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc (TTNP), is a biopharmaceutical company specializing in the development of products for treatment of central nervous system diseases (CNS). TTNP's chief asset is Probuphine, a slow-release implant medication of buprenorphine hydrochloride. Buprenorphine hydrochloride is a semi-synthetic opioid considered to be more than 25 times more effective than the coveted morphine pain reliever. The drug is designed to maintain a stable, 24/7 blood level of the formulation in patients for up to six months, ensuing a single treatment. First launched in 2011, is now available in a seven day transdermal patch for the of chronic pain patients. The transdermal patch is subdermally implanted in the patient's upper arms, providing continuous pain relief. This form of administration reduces the illegal use of the drug and helps prevent accidental overdose which can become prevalent with oral medication forms. In October 2012, the FDA received request for approval for the new drug to be administered also for opioid dependency, to combat opioid addictions.

Titan Pharmaceuticals Inc, hopes to enter into several partnerships other pharmaceutical companies and commercialize Probuphine in U.S. and foreign markets.

Secondly, Titan Pharmaceuticals Inc. currently is entitled to 8-10% of net sales for the drug Fanapt (iloperidone), which is an antipsychotic approved by the FDA (May 2009) for the treatment of schizophrenia and marketed by Novartis Pharma AG ("Novartis") in the U.S. This sublicense agreement with Novartis, is based on a patent which will not expire until October 2016.

TTNP's stock price is currently $1.68. The price over the past 52 weeks has a range of $0.60 to $2.53, with a market cap of $126.36 million. The company is poised to make huge gains again soon. Previous close $1.73.

To stay updated and informed on all changes with TTNP and many other companies, subscribe to bestdamnpennys4bucks.com and receive a free newsletter today.

TTNP

Sunil Bhonsle

Robert E. Farrell

Brian Crowley

http://www.titanpharm.com/

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.